BPTSY (Biophytis) 3-Year RORE % : -83.14% (As of Jun. 2025)


BPTSY Biophytis SA BPTSY
18 GF Score
Price $0.25
! 5 Warning Signs
View Full Analysis

What is Biophytis 3-Year RORE %?

Biophytis BPTSY 18 3-Year RORE % is -83.14 as of Jun. 2025. GuruFocus rates BPTSY with a GF Score™ of 18/100. The stock has 5 warning signs investors should review. Among 1,294 Biotechnology companies, Biophytis ranks worse than 91.73% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Biophytis's 3-Year RORE % for the quarter that ended in Jun. 2025 was -83.14%.

The industry rank for Biophytis's 3-Year RORE % or its related term are showing as below:

BPTSY's 3-Year RORE % is ranked worse than
91.73% of 1294 companies
in the Biotechnology industry
Industry Median: -11.54 vs BPTSY: -83.14

Biophytis  (OTCPK:BPTSY) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Biophytis 3-Year RORE % Related Terms


Biophytis 3-Year RORE % Historical Data

* Premium members only.

The historical data trend for Biophytis's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biophytis 3-Year RORE % Chart

Biophytis Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
3-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -21.42 -45.07 -40.93 -55.17 -74.69

Biophytis Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -32.32 -55.17 -66.34 -74.69 -83.14

BPTSY vs VRTX, REGN, ALNY: 3-Year RORE % Comparison

For the Biotechnology subindustry, Biophytis's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biophytis 3-Year RORE % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biophytis's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Biophytis's 3-Year RORE % falls into.


BPTSY
18GF Score
Biophytis SA BPTSY
3-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biophytis 3-Year RORE % Calculation

Biophytis's 3-Year RORE % for the quarter that ended in Jun. 2025 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( -6.545--350.59 )/( -413.833-0 )
=344.045/-413.833
=-83.14 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Jun. 2025 and 3-year before.

Frequently Asked Questions Learn more about 3-Year RORE % →
What does a 3-Year RORE % of -83.14 mean?
Biophytis (BPTSY) has a 3-Year RORE % of -83.14 as of Jun. 2025. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Biophytis and its competitors. According to the industry distribution chart, Biophytis ranks #1187 out of 1294 companies in the Biotechnology industry, placing it in the top 91.7%.
Is Biophytis' 3-Year RORE % too high?
Biophytis' current 3-Year RORE % is -83.14. Based on the distribution chart, Biophytis ranks #1187 out of 1294 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Biophytis has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Biophytis' 3-Year RORE % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Biophytis ranks #1187 out of 1294 companies for 3-Year RORE %. This places Biophytis in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Biotechnology company?
A good 3-Year RORE % depends on the Biotechnology industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Biophytis and its competitors. Biophytis's current 3-Year RORE % is -83.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biophytis stock overvalued right now?
Biophytis (BPTSY) has a current 3-Year RORE % of -83.14. The current 3-Year RORE % is -83.14. Biophytis' overall GF Score™ is 18/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Biophytis (BPTSY), the current 3-Year RORE % is -83.14 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biophytis Business Description

Address BC 9, Batiment A 4eme etage, 4 Place Jussieu, Sorbonne University, Paris, FRA, 75005
Biophytis SA is a France-based clinical-stage biotechnology company engaged in the development of drug candidates for the treatment of age-related and respiratory diseases. The company focuses on therapies that target degenerative processes associated with aging and improve functional outcomes. Its drug candidate, BIO101, is an orally administered small molecule under development for neuromuscular and respiratory indications, including sarcopenia, Duchenne muscular dystrophy (DMD), and respiratory failure.
18GF Score

Get the complete analysis for BPTSY

3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.25
Price